New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 7, 2012
08:34 EDTSRPTSarepta updates data from Study 202 of steplirsen for treatment of DMD
Sarepta Therapeutics announced updated data from Study 202, its open-label, Phase IIb extension study of eteplirsen for the treatment of Duchenne muscular dystrophy, or DMD. Patients treated with eteplirsen for 62 weeks and evaluable on ambulatory measures maintained a statistically significant clinical benefit on the primary clinical outcome measure, the 6-minute walk test, or 6MWT, compared to patients who received placebo for 24 weeks followed by 38 weeks of eteplirsen treatment. The mITT consisted of 10 of the enrolled 12 patients, and excludes two patients who showed signs of rapid disease progression and lost ambulation by week 24. The placebo/delayed-treatment cohort (n=4) also demonstrated stability in walking distance from week 36 through week 62 with a less than 10 meter change over this timeframe, the period in which dystrophin was likely produced, with confirmation of significant dystrophin levels at week 48 through analysis of muscle biopsies in these patients.
News For SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2015
10:32 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
10:13 EDTSRPTOptions with increasing implied volatility
Options with increasing implied volatility: ESPR SRPT CX RAX YY SPLK QIHU HFC OWW BBY
July 29, 2015
06:38 EDTSRPTBioMarin price target raised to $163 from $147 at Piper Jaffray
Subscribe for More Information
July 28, 2015
10:38 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
July 27, 2015
10:40 EDTSRPTIsis 'most obvious' Biogen takeover target, TheStreet's Feuerstein says
Subscribe for More Information
July 22, 2015
17:06 EDTSRPTSarepta announce publication of Phase I clinical data of AVI-7288
Subscribe for More Information
July 20, 2015
14:32 EDTSRPTFDA panel likely to review Sarepta, BioMarin drugs in November, TheStreet says
Subscribe for More Information
11:03 EDTSRPTSarepta rises after Roth says added data can keep it ahead of BioMarin
Subscribe for More Information
10:13 EDTSRPTOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use